Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNittayananta W.
dc.contributor.authorKemapunmanus M.
dc.contributor.authorAmornthatree K.
dc.contributor.authorTalungchit S.
dc.contributor.authorSriplung H.
dc.description.abstractBackground: The objectives of this study were to determine (i) oral hBD2 expression in HIV-infected subjects compared with non-HIV controls, (ii) the expression of oral hBD2 in HIV-infected subjects with antiretroviral therapy (ART) compared with those without ART, and (iii) factors associated with the expression of oral hBD2. Methods: Oral examination and punched biopsy on buccal mucosa were performed in HIV-infected subjects with and without ART, and non-HIV individuals. The expression of hBD2 mRNA was determined by quantitative real-time PCR. Saliva samples of both un-stimulated and stimulated saliva were collected and analyzed for hBD2 levels using ELISA. Student's t-test and nonparametric multi-way ANOVA test were used for comparison of measurements between or among groups. Results: One hundred and fifty-seven HIV-infected subjects were enrolled: 99 on ART (age range, 23-57years; mean 39years), 58 not on ART (age range, 20-59years; mean 34years), and 50 non-HIV controls (age range, 19-59years; mean 36years). The most common ART regimen was two nucleoside reverse transcriptase inhibitors+one non-nucleoside reverse transcriptase inhibitor. Salivary levels of hBD2 were significantly increased in HIV infection (P<0.001). The levels of hBD2 in stimulated saliva were also found to be significantly different between HIV-infected subjects who were and were not on ART (P<0.001). No significant difference was observed with the expression of hBD2 mRNA. Conclusion: Oral innate immunity is affected by HIV infection and use of ART. Salivary hBD2 levels may be the useful biomarkers to monitor those on long-term ART who are at risk of developing oral infections and malignant transformation. © 2012 John Wiley & Sons A/S.
dc.subjectbeta defensin 2
dc.subjectRNA directed DNA polymerase inhibitor
dc.subjectcheek mucosa
dc.subjectcontrolled study
dc.subjectcross-sectional study
dc.subjectenzyme linked immunosorbent assay
dc.subjecthighly active antiretroviral therapy
dc.subjectHuman immunodeficiency virus infected patient
dc.subjectHuman immunodeficiency virus infection
dc.subjecthuman tissue
dc.subjectmajor clinical study
dc.subjectmouth examination
dc.subjectpriority journal
dc.subjectprotein expression
dc.subjectreal time polymerase chain reaction
dc.subjectsaliva analysis
dc.subjectAnalysis of Variance
dc.subjectAnti-HIV Agents
dc.subjectAntimicrobial Cationic Peptides
dc.subjectCase-Control Studies
dc.subjectCD4 Lymphocyte Count
dc.subjectCross-Sectional Studies
dc.subjectHIV Infections
dc.subjectImmunity, Innate
dc.subjectMiddle Aged
dc.subjectMouth Mucosa
dc.subjectRegression Analysis
dc.subjectReverse Transcriptase Inhibitors
dc.subjectReverse Transcriptase Polymerase Chain Reaction
dc.subjectSalivary Proteins and Peptides
dc.subjectStatistics, Nonparametric
dc.subjectViral Load
dc.subjectYoung Adult
dc.titleOral human β-defensin 2 in HIV-infected subjects with long-term use of antiretroviral therapy
dc.identifier.bibliograpycitationJournal of Oral Pathology and Medicine. Vol 42, No.1 (2013), p.53-60
Appears in Collections:Scopus 1983-2021

Files in This Item:
There are no files associated with this item.

Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.